News

Access has released an update on its clinical development strategy for ProLindac, a novel DACH platinum drug that has shown to be active in many solid tumors in

Amgen has reported positive top-line results from a pivotal phase 3 head-to-head trial evaluating denosumab. The study of denosumab, administered subcutaneously versus Zometa administered as an intravenous (IV)

Elan Drug Technologies, a business unit of Elan Corporation, has announced the first approval of an injectable formulation using its proprietary NanoCrystal technology. The company said that earlier

Shire has reported positive results from the first of three phase III studies of velaglucerase alfa, its enzyme replacement therapy for the treatment of Type 1 Gaucher disease.

Zogenix and Astellas have entered into an exclusive co-promotion agreement for Sumavel DosePro (sumatriptan injection) needle-free delivery system.   Sumavel DosePro, a needle-free delivery system for subcutaneous sumatriptan,

MAP Pharmaceuticals has reported net loss for the quarter ended June 30, 2009 of $5 million, as compared to $16.5 million during the same period in 2008. The

Watson has received approval from FDA on its Abbreviated New Drug Applications (ANDAs) for metoprolol succinate extended-release Toprol tablets USP, in the 25mg and 50mg strengths. Metoprolol succinate

Teijin, a Japan-based specialty chemicals company, has posted net sale of ¥166 billion for the second quarter of 2009, a decrease of 29.8% as compared to ¥236 billion

Æterna Zentaris reported that Keryx has reached an agreement with FDA regarding a Special Protocol Assessment (SPA) on the design of a phase 3 trial for PI3K/Akt pathway